Not all intravenous immunoglobulin preparations are equally well tolerated

Acta Dermato-Venereologica

Volumn 90, Issue 5, 2010, Pages 494-497

  Feldmeyer, Laurence ^a   Benden, Christian ^b   Haile, Sarah R ^b   Boehler, Annette ^b   Speich, Rudolf ^b   French, Lars E ^a   Hofbauer, Günther F L ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Adverse drug reaction; Hypogammaglobulinemia; Intravenous immunoglobulin; Lung transplantation; Prevention; Toxic epidermal necrolysis

Indexed keywords

ADRENALIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; NONSTEROID ANTIINFLAMMATORY AGENT; REDIMUNE NF LIQUID; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ARTICLE; ASEPTIC MENINGITIS; ATOPIC DERMATITIS; CHEST TIGHTNESS; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; COLLAPSE; CYTOMEGALOVIRUS INFECTION; DERMATOMYOSITIS; DISEASE SEVERITY; DIZZINESS; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EPSTEIN BARR VIRUS INFECTION; FEMALE; FEVER; HEART INFARCTION; HUMAN; IMMUNOGLOBULIN DEFICIENCY; IMMUNOGLOBULIN G DEFICIENCY; INDUCED HYPOTENSION; LYMPHOPROLIFERATIVE DISEASE; MALE; MUSCLE CRAMP; NAUSEA; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; REHYDRATION; SIDE EFFECT; SORE THROAT; STROKE; SYNCOPE; THROMBOEMBOLISM; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WHEEZING;

ADULT; AGED; CHEMISTRY, PHARMACEUTICAL; CHILLS; DRUG SUBSTITUTION; FEMALE; FEVER; HEADACHE; HUMANS; HYPOTENSION; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MUSCLE CRAMP; NAUSEA; RETROSPECTIVE STUDIES; SWITZERLAND; TIME FACTORS; VOMITING; YOUNG ADULT;

EID: 77957670080     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0900     Document Type: Article

References (16)

1. Ishii N, Hashimoto T, Zillikens D, Ludwig RJ. High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases. Clin Rev Allergy Immunol 2010; 38: 186-195.
2. Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol 2007; 87: 206-218. (Pubitemid 47226887)
3. Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007; 6: 257-259. (Pubitemid 46274552)
4. Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res 2007; 38: 122-132. (Pubitemid 47574903)
5. Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol 2008; 122: 1238-1239.
6. Carbone J. Adverse reactions and pathogen safety of intravenous immunoglobulin. Curr Drug Saf 2007; 2: 9-18.
7. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006; 6: 535-542. (Pubitemid 43295458)
8. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29: 173-184. (Pubitemid 43041668)
9. Hooper JA. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin North Am 2008; 28: 765-778, viii.
10. Roifman CM, Schroeder H, Berger M, Sorensen R, Ballow M, Buckley RH, et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol 2003; 3: 1325-1333.
11. Brennan VM, Salome-Bentley NJ, Chapel HM. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 2003; 133: 247-251.
12. R Development Core Team (2009). R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. [cited 2009 Dec 9]. Available from: http://www.R-project. org.
13. Vecchietti G, Kerl K, Prins C, Kaya G, Saurat JH, French LE. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature. Arch Dermatol 2006; 142: 213-217.
14. Zhang G, Lopez PH, Sheikh KA. Comparison of different brands of IVIg in an in vitro model of immune neuropathy. J Neuroimmunol 2006; 173: 200-203.
15. Nydegger UE, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Saf 1999; 21: 171-185.
16. Benden C, Speich R, Hofbauer GF, Irani S, Eich-Wanger C, Russi EW, et al. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation 2008; 86: 1625-1627.